MET and neoplasm: Accordingly, kinase inhibitors or antibodies induced objective responses in patients with (or preclinical models of) MET-addicted tumours, including non-small cell lung cancer (NSCLC), lung squamous carcinoma, gastric cancer, colorectal adenocarcinoma, melanoma, gliomas, and renal cancer1,3–14.